Immune Response to Polyomavirus Infection

对多瘤病毒感染的免疫反应

基本信息

批准号：
7787053
负责人：
PARMJEET S RANDHAWA
金额：
$ 39.6万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-04-01 至 2012-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7787053
关键词：
Acute Adoptive Immunotherapy Allografting Antibodies Antigen-Presenting Cells Antigens Autoantigens BK Virus Binding Biological Assay Biological Factors Biopsy CD4 Positive T Lymphocytes Calcineurin inhibitor Cell physiology Cells Clinical Clinical Course of Disease Complication Cyclosporine Cyclosporins Cytotoxic T-Lymphocytes Data Development Diagnosis Disease Disease Outcome Distress Early Diagnosis Epitopes Failure Frequencies Funding Future Goals Grant Helper-Inducer T-Lymphocyte Human Human Herpesvirus 4 Humoral Immunities Hypersensitivity Immune response Immune system Immunity Immunoglobulin A Immunoglobulin M Immunologic Factors Immunosuppression Immunosuppressive Agents Immunotherapy Incidence Individual Infection Injury Interferon Type II Interleukin-10 Interleukin-5 JC Virus Kidney Kidney Diseases Kidney Transplantation Laboratories Latent Virus Lead Literature Liver Lytic Phase Measurement Measures Mediating Medical center Memory Memory Loss Monitor Morbidity - disease rate Needle biopsy procedure Organ Organ Transplantation Pathogenesis Patients Peptides Perioperative Peripheral Blood Mononuclear Cell Pharmaceutical Preparations Physiologic pulse Polyomavirus Polyomavirus Infections Production Proteins Protocols documentation Recombinants Regimen Regulatory T-Lymphocyte Reporting Research Research Personnel Risk Risk Estimate Serological Serotyping Serum Simian virus 40 Sirolimus Solid Subgroup T-Lymphocyte Tacrolimus Testing Time Tissues Toxic effect Transplant Recipients Transplantation United States National Institutes of Health Vaccines Viral Viral Antigens Viral Load result Viral Tumor Antigens Viremia Virus Diseases Virus Latency antigen binding base cell mediated immune response chemokine cytokine cytotoxic enzyme linked immunospot assay falls high risk liver transplantation lymphoblastoid cell line mycophenolate mofetil outcome forecast prognostic programs response sialosyl-T antigen tool vaccine development

项目摘要

Polyomavirus BK nephropathy is an increasingly recognized complication of organ transplantation. It is associated with significant morbidity & 20-50% risk of graft loss. We propose to study how the immune system reacts to BK virus infection. The ultimate long-term goal of our proposal is to generate data, which will help in the development of vaccines & immunotherapy protocols against this disease. The study will have the following specific aims: (1) To determine the influence of donor and host recipient serologic status on the clinical course of BK virus infection after liver and kidney transplantation. (2) To characterize the anti-BKV T-helper (Th) response in BK virus infection in (a) healthy subjects, (b) kidney transplant recipients, and (c) liver transplant recipients (3) To characterize the T-cytotoxic cell response to BK virus in (a) healthy subjects, (b) kidney transplant recipients, and (c) liver transplant recipients. The information generated during the course of this study will permit earlier diagnosis of BK virus infection infection, prior to advanced and potentially irreversible tissue injury. The research proposed will also promote better understanding of the biologic factors that initiate and perpetuate viral nephropathy. This, in turn, will help us to better predict the clinical course of the disease in individual patients, and help devise more effective forms of anti-viral therapy.

多瘤病毒 BK 肾病是一种日益被认识的器官移植并发症。这是与显着的发病率和 20-50% 的移植物丢失风险相关。我们建议研究免疫如何系统对 BK 病毒感染做出反应。我们提案的最终长期目标是生成数据，这将有助于开发针对这种疾病的疫苗和免疫治疗方案。该研究将有具体目标如下： (1) 确定供体和宿主受体血清学状态对临床病程的影响肝肾移植后BK病毒感染的研究进展. (2) 表征 (a) 健康人 BK 病毒感染中的抗 BKV T 辅助细胞 (Th) 反应受试者，(b) 肾移植受者，和 (c) 肝移植受者 (3) 表征 (a) 健康受试者、(b) 肾脏中 T 细胞毒性细胞对 BK 病毒的反应移植受者，和 (c) 肝移植受者。本研究过程中产生的信息将有助于对 BK 病毒感染进行早期诊断感染，发生在高级且可能不可逆的组织损伤之前。拟议的研究还将促进更好地了解引发和延续病毒性肾病的生物因素。反过来，这将帮助我们更好地预测个体患者疾病的临床病程，并帮助设计出更有效的方案形式的抗病毒治疗。